On April 4, 2023, AIM ImmunoTech Inc. (the "Company") reported an Unrestricted Grant Agreement with Erasmus University Medical Center ("EUMC") pursuant to which EUMC will use its best efforts to diligently carry out immune monitoring in pancreatic cancer patients (Filing, 8-K, AIM ImmunoTech, APR 4, 2023, View Source [SID1234629894]). On April 5, 2023, the Company entered into a Consulting Agreement with Casper H.J. van Eijck pursuant to which, among other things, Dr. van Eijck will assist the Company in recruiting and assisting sites outside of the Netherlands to participate in clinical trials evaluating Ampligen for the treatment of pancreatic cancer. The foregoing summaries of the agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the these agreements, which are attached as Exhibit 10.1 and 10. 2 to this Current Report on Form 8-K and incorporated herein by reference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!